Review: Evidence for major benefits and harms of antidiabetic agents for diabetes with heart failure is limited

January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p4
Academic Journal
The article presents a clinical study that evaluates the relation between antidiabetic therapy, morbidity and mortality in patients with heart failure and diabetes. A randomized controlled trials showed that the metformin was associated with lower risk for mortality compared to other antidiabetic drugs. The study concludes that the metformin and thiazolidinediones are linked with reduced risk, but insulin is linked with increased risk for mortality in patients with heart failure and diabetes.


Related Articles

  • Does metformin prevent diabetes in at-risk adults? Mangahas, Theresa; Huang, Grace; Neher, Jon; Safranek, Sarah; Kelsberg, Gary // Journal of Family Practice;Aug2013, Vol. 62 Issue 8, p436 

    The article presents an answer to a question of whether metformin helps in reducing the risks of diabetes in adults.

  • Older diabetes drugs produced similar glycemic effects as new drugs. Kalvaitis, Katie // Cardiology Today;Jan2008, Vol. 11 Issue 1, p14 

    The article discusses research being done on the glycemic effects of old diabetes drugs. It references a study by Shari Bolen and colleagues, published in "Annals of Internal Medicine." Researchers reviewed different oral diabetes drugs including thiazolidinediones (TZD), metformin and...

  • Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Nauck, Michael; Frid, Anders; Hermansen, Kjeld; Shah, Nalini S.; Tankova, Tsvetalina; Mitha, Ismail H.; Zdravkovic, Milan; Düring, Maria; Matthews, David R. // Diabetes Care;Jan2009, Vol. 32 Issue 1, p84 

    OBJECTIVE -- The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS-- In this...

  • Incorporating New Medications in Diabetes Care. Comi, Richard J. // Annals of Internal Medicine;11/3/2015, Vol. 163 Issue 9, p719 

    The article focuses on the encorporation of new medications for patients suffering with diabetes. It refers to the University Group Diabetes Program (UGDP) study which reflected on the efficacy and safety of using biguanides, thiazolidinediones and insulin glargine, for treatment of patients...

  • Modernes Therapieschema zur Behandlung von Patienten mit Diabetes mellitus Typ 2.  // Praxis (16618157);9/4/2013, Vol. 102 Issue 18, p1083 

    No abstract available.

  • COMMENTARY: Review: Evidence for major benefits and harms of antidiabetic agents for diabetes with heart failure is limited. Lingegowda, Vijaykumar // ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, p4 

    The author comments on the study concerning the relationship of antidiabetic drugs with heart diseases. He asserts that the randomized controlled trial presents a potential selection bias in different treatment groups such as the insulin therapy. He suggests that the study should take a...

  • Nateglinide Alone and in Combination With Metformin Improves Glycemic Control by Reducing Mealtime Glucose Levels in Type 2 Diabetes. Horton, Edward S.; Clinkingbeard, Cynthia; Gatlin, Marjorie; Foley, James; Mallows, Susan; Shen, Sharon // Diabetes Care;Nov2000, Vol. 23 Issue 11, p1660 

    Features a study which evaluated the efficacy of using nateglinide and metformin alone and in combination in glycemic control in type 2 diabetic patient controlled by diet. Information on nateglinide and metformin, two antidiabetic agents; Study design; Statistical analysis; Efficacy parameters...

  • Metformin does not harm diabetic patients with heart failure.  // Journal of Family Practice;Dec2007, Vol. 56 Issue 12, p996 

    The article focuses on the risk of oral hypoglycemics to patients with diabetes and heart failure. It is stated that some evidence suggests the control of blood glucose to be associated with worse outcomes in patients with heart failure. It is noted that antidiabetic agents such as metformin may...

  • An Overexpression of Icam-1 in Mild Hyperhomocysteinemia and Hyperglycemia - A Study of Antidiabetics Administration Effect. Bačun, Tatjana; Belovari, Tatjana; Včev, Aleksandar; Mihaljević, Ivan; Hanich, Toni; Fijačko, Vladimir; Glavaš-Obrovac, Ljubica // Croatica Chemica Acta;Jun2012, Vol. 85 Issue 2, p185 

    Elevated plasma homocysteine is connected to atherosclerosis and increased cerebrovascular and ischemic heart disease especially in the patients with type 2 diabetes. Effects of metformin (10 µg mL-1), insulin (1 mUI mL-1), and their combination administration in condition of mild...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics